Ergomed
Ergomed plc, a leading provider of specialised services to the pharmaceutical industry, is headquartered in Great Britain. Founded in 1997, the company has established a strong presence in key operational regions, including Europe and North America. Ergomed focuses on two main business areas: drug development and post-marketing services, offering a unique blend of expertise that enhances the efficiency of clinical trials. With a commitment to quality and innovation, Ergomed provides a range of core services, including clinical research, pharmacovigilance, and regulatory affairs. The company has achieved notable milestones, such as its successful listing on the London Stock Exchange, solidifying its position as a trusted partner in the life sciences sector. Ergomed's dedication to tailored solutions and client satisfaction sets it apart in a competitive market.
DitchCarbon Score
How does Ergomed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ergomed's score of 29 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ergomed's reported carbon emissions
In 2022, Ergomed reported total carbon emissions of approximately 46,150 kg CO2e globally. This figure includes 730 kg CO2e from Scope 1 emissions, primarily from stationary combustion, and 14,290 kg CO2e from Scope 2 emissions related to purchased electricity. Additionally, Scope 3 emissions, which encompass business travel, accounted for about 17,290 kg CO2e. In 2021, Ergomed's emissions were slightly higher, totalling around 60,650 kg CO2e, with Scope 1 emissions at 60 kg CO2e and Scope 2 emissions at 25,450 kg CO2e. The Scope 3 emissions for that year were approximately 17,530 kg CO2e, again primarily from business travel. The company has demonstrated a commitment to reducing its carbon footprint, as evidenced by a significant decrease in total emissions from 80,130 kg CO2e in 2020 to 46,150 kg CO2e in 2022. However, Ergomed has not publicly set specific reduction targets or climate pledges, indicating a potential area for future commitment in line with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | - | 00 | 00 | 000 |
| Scope 2 | - | 00,000 | 00,000 | 00,000 |
| Scope 3 | 39,710 | 00,000 | 00,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ergomed is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
